Generic Medicine Info
Hypersensitivity to aztreonam.
Special Precautions
History of β-lactam hypersensitivity. Renal and hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor for signs of anaphylaxis during 1st dose; periodic LFT. Consider measuring FEV1 prior to initiation of inhalation therapy.
Adverse Reactions
Inhalation: Cough, nasal congestion, fever, wheezing, bronchospasm. IM: Pain or swelling. IV: Phlebitis or thrombophlebitis. Hypersensitivity reactions e.g. urticaria, rashes, exfoliative dermatitis, angioedema, bronchospasm, eosinophilia. GI effects e.g. nausea, vomiting, abnormal taste, mouth ulcer. Overgrowth of non-susceptible organisms e.g. gm+ve cocci; pseudomembranous colitis or GI bleeding; jaundice, hepatitis, increased liver enzymes and, prothrombin and partial thromboplastin times prolongation. Rarely, anaphylaxis, toxic epidermal necrolysis.
Potentially Fatal: Clostridium difficile-associated diarrhoea from mild diarrhoea to fatal colitis.
Drug Interactions
Concurrent use w/ oral anticoagulants may increase prothrombin time.
CIMS Class
Other Beta-Lactams
ATC Classification
J01DF01 - aztreonam ; Belongs to the class of monobactams. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on aztreonam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in